Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections

References

• McCaig LF, McDonald LC, Mandal S, et al. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006 Nov;12(11):1715–1723.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009 Sep;15(9):1516–1518.
   PubMed Web of Science ®Google Scholar
• CDC Threat Report, 2013. [cited 2016 Aug 14]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/
   Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15;59(2):e10–52.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, et al. Two study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007 Oct;51(10):3612–3616.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683–1693.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014 Jun 5;370(23):2180–2190.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004 Jun 15;38(12):1673–1681.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002 Jun 1;34(11):1481–1490.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696–705.
   PubMed Web of Science ®Google Scholar
• Bowen AC, Lilliebridge RA, Tong SY, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol. 2012 Dec;50(12):4067–4072.
   PubMed Web of Science ®Google Scholar
• Bergmann R, van der Linden M, Chhatwal GS, et al. Factors that cause trimethoprim resistance in Streptococcus pyogenes. Antimicrob Agents Chemother. 2014;58(4):2281–2288.
   PubMed Web of Science ®Google Scholar
• Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J. 2005 Jul;24(7):622–626.
   PubMed Web of Science ®Google Scholar
• Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2006 Apr;25(4):349–353.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. Trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016 Mar 1;62(5):545–551.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014 Nov;58(11):6471–6476.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mann HJ, Keshtgarpour M, et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs. 2011 Nov;34(11):1067–1074.
   PubMed Web of Science ®Google Scholar
• McConeghy KW, Liao S, Clark D, et al. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother. 2014 Dec;58(12):7093–7097.
   PubMed Web of Science ®Google Scholar
• Trius grows as lead antibiotic moves forward. The San Diego Union-Tribune. [ cited 2015 Sep 3]. Available from: http://www.sandiegouniontribune.com/news/2011/oct/31/trius-grows-lead-antibiotic-moves-forward/
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=11476460. [ cited 2016Aug 29]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11476460
   Google Scholar
• Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 Jul;57(7):3060–3066.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect Dis Ther. 2015 Feb 24;4:1–14.
   PubMed Web of Science ®Google Scholar
• Im WB, Choi SH, Park JY, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem. 2011 Apr;46(4):1027–1039.
   PubMed Web of Science ®Google Scholar
• Saini JS, Homeyer N, Fulle S, et al. Determinants of the species selectivity of oxazolidinone antibiotics targeting the large ribosomal subunit. Biol Chem. 2013 Nov;394(11):1529–1541.
   PubMed Web of Science ®Google Scholar
• Chen KH, Huang YT, Liao CH, et al. In vitro activities of tedizolid and linezolid against gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother. 2015 Oct;59(10):6262–6265.
   PubMed Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010 Dec;54(12):5337–5343.
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004 Feb;23(2):113–119.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011 Dec;1241:48–70.
   PubMed Web of Science ®Google Scholar
• McCusker KP, Fujimori DG. The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance. ACS Chem Biol. 2012 Jan 20;7(1):64–72.
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother. 2010 May;54(5):2063–2069.
   PubMed Web of Science ®Google Scholar
• Schaadt R, Sweeney D, Shinabarger D, et al. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother. 2009 Aug;53(8):3236–3239.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008 Dec;52(12):4442–4447.
   PubMed Web of Science ®Google Scholar
• Morata L, Senneville E, Bernard L, et al. A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther. 2014 Dec;3(2):235–243.
   PubMedGoogle Scholar
• Si S, Durkin M, Mercier M, et al. Successful treatment of prosthetic joint infection due to vancomycin-resistant Enterococci with tedizolid. Infect Dis Clin Pract. 2016. Available from: http://journals.lww.com/infectdis/Abstract/publishahead/Successful_Treatment_of_Prosthetic_Joint_Infection.99168.aspx
   Google Scholar
• Locke JB, Zurenko GE, Shaw KJ, et al. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014 Jan;58(Suppl 1):S35–42.
   PubMed Web of Science ®Google Scholar
• Chen H, Yang Q, Zhang R, et al. In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant gram-positive pathogens: a multicentre study in China. Int J Antimicrob Agents. 2014 Sep;44(3):276–277.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Liu W, Kulawy R, et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011 Nov;55(11):5300–5305.
   PubMed Web of Science ®Google Scholar
• Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015 Oct 15;61(8):1315–1321.
   PubMed Web of Science ®Google Scholar
• Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012 02/04/received 04/16/rev-request 06/14/accepted;563:4713–4717.
   PubMedGoogle Scholar
• Prokocimer P, de Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. Jama. 2013 Feb 13; 309(6):559–569.
   PubMed Web of Science ®Google Scholar
• Betriu C, Morales G, Rodriguez-Avial I, et al. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010 May;54(5):2212–2215.
   PubMed Web of Science ®Google Scholar
• Chen K-H, Huang Y-T, Liao C-H, et al., In vitro activities of tedizolid and linezolid against gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother. 2015 09/18, 02/13/received, 04/29/rev-request, 07/20/accepted;5910:6262–6265.
   PubMed Web of Science ®Google Scholar
• Sivextro [package insert]. [ cited 2016 Aug 30]. Available from: sivextro.com
   Google Scholar
• Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011 Feb;55(2):583–592.
   PubMed Web of Science ®Google Scholar
• Flanagan SD, Bien PA, Munoz KA, et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014 Mar;34(3):240–250.
   PubMed Web of Science ®Google Scholar
• Kisgen JJ, Mansour H, Unger NR, et al. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm. 2014 Apr 15;71(8):621–633.
   PubMedGoogle Scholar
• Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275–1284.
   PubMed Web of Science ®Google Scholar
• Wong E, Rab S. Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections. P T. 2014 Aug;39(8):555–579.
   PubMedGoogle Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011 May;66(Suppl 4):iv7–iv15.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864–871.
   PubMed Web of Science ®Google Scholar
• Tessier PR, Keel RA, Hagihara M, et al. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother. 2012 May;56(5):2342–2346.
   PubMed Web of Science ®Google Scholar
• Ortiz-Covarrubias A, Fang E, Prokocimer PG, et al. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. Braz J Infect Dis. 2016 Mar-Apr;20(2):184–192.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, Bien P, Deanda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Sep;56(9):4608–4613.
   PubMed Web of Science ®Google Scholar
• Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012 May;56(5):2627–2634.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Flanagan SD, Arrieta AC, et al. Pharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescents. Pediatr Infect Dis J. 2016 Jun;35(6):628–633.
   PubMed Web of Science ®Google Scholar
• Iqbal MM, Basil MJ, Kaplan J, et al. Overview of serotonin syndrome. Ann Clin Psychiatry. 2012 Nov;24(4):310–318.
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012 Apr;21(4):515–522.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002 Aug;46(8):2723–2726.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fang E, Minassian SL, et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198–7204.
   PubMed Web of Science ®Google Scholar
• Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007 Aug;27(8):1189–1197.
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015 Jan;59(1):178–185.
   PubMed Web of Science ®Google Scholar
• Douros A, Grabowski K, Stahlmann R. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015 [2015 Dec 02];11(12):1849–1859.
   PubMed Web of Science ®Google Scholar
• Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011 Feb;51(2):229–236.
   PubMed Web of Science ®Google Scholar
• Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections – focus on tedizolid. Ther Clin Risk Manag. 2015;11:857–862.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. U.S National Institutes of Health. [cited 2017 Jan 20]. Available from: www.clinicaltrials.gove/ct2/home.
   Google Scholar